Multibody-Enabled Lysosome-Targeting Drug Conjugates for Target Protein Degradation and Combination Therapy

Lei Wang, Luping Chen, Shuai Yao, Xiaoli Tian, li ping, Pan Tan, Qi Sun, Yiyang Gu, Yixuan Wen, Jin Huang, Simin Chen, Dong-Yuan Lv, Wei Wu, Liming Ouyang, Liqiang Fan, Wei Huang, Fujun Wang, Yuzheng Zhao, Jian Zhao, Jingyu Zhang, Hong Liang, Feng TangResearch Square 2026 · DOI

Introduction

Targeted cancer therapy has been revolutionized by two primary technologies: Antibody-Drug Conjugates (ADCs) and Lysosome-Targeting Chimeras (LYTACs). ADCs deliver cytotoxic payloads to specific cells, while LYTACs facilitate the degradation of disease-causing membrane proteins by shuttling them to the lysosome. Despite their success, both platforms face significant "bottleneck" issues. ADCs are often limited by the slow natural internalization rates of target proteins, and LYTACs typically rely on a narrow range of receptors, requiring complex chimeric designs that are difficult to engineer.

To address these limitations, researchers have developed a versatile therapeutic platform termed "Multibodies." This system utilizes a fungal immunomodulatory protein, LZ-8, as a modular scaffold to create a unified strategy for simultaneous protein degradation and drug delivery.

Engineering the LZ-8 "Internalization Engine"

The core of the Multibody platform is the fungal protein LZ-8, which acts as a natural "internalization engine" with a high affinity for lysosomal trafficking. However, in its wild-type form, LZ-8 is overly "sticky," binding to a wide array of receptors and causing toxic lysosomal dysfunction.

Through rational protein engineering and molecular docking, the research team identified a single amino acid residue, Y84, responsible for this promiscuous binding. By mutating this residue to Alanine (Y84A), they created an optimized variant called LZ-8-2.3. This engineered scaffold retains its potent lysosome-homing ability while eliminating off-target toxicity, making it a safe and effective vehicle for therapeutic delivery.

The LYTAC-DC Mechanism

By fusing the LZ-8-2.3 scaffold with specific nanobodies and chemically linking them to drug payloads (such as MMAE or Doxorubicin), the team created LYTAC-DCs (Lysosome-Targeting Chimera-Drug Conjugates). This modular assembly allows for a "one-two punch" against cancer cells: the nanobody grabs a target protein (like EGFR, PD-L1, or HER2) for degradation, while the scaffold ensures efficient entry into the lysosome for both protein breakdown and site-specific drug release.

Schematic of the LYTAC-DC mechanism: combining target protein degradation with site-specific drug release.

AI-Assisted Evolution and Modularity

To further simplify the design, the researchers employed a protein language model called ProSST for AI-assisted directed evolution. This allowed them to evolve the LZ-8 scaffold itself into a specific binder, resulting in LYTA-DCs (Lysosome-Targeting Drug Conjugates). These non-chimeric, single-agent molecules can bind targets directly without the need for an additional nanobody, representing a significant step toward smaller, more stable, and more "druggable" protein therapeutics.

Preclinical Validation and Results

The platform was rigorously tested across various biological models, including HeLa, A431, and MDA-MB-231 cell lines, as well as drug-resistant lung cancer models. Key findings include:

  • High Potency: The engineered LYTAC-DC achieved robust EGFR degradation with a DC50 as low as 11.87 nM in A431 cells.
  • Overcoming Resistance: In patient-derived organoids (PDXO) with triple-mutant EGFR (Del19/T790M/C797S), the platform significantly inhibited tumor growth where standard inhibitors like osimertinib failed.
  • In Vivo Efficacy and Safety: In murine xenograft models, the conjugates suppressed tumor growth significantly without causing weight loss or organ damage, validating the safety of the LZ-8-2.3 scaffold.

Conclusion and Future Directions

The Multibody platform represents a paradigm shift in targeted therapy, moving toward programmable, single-agent molecules that can navigate complex cellular pathways. While the results are promising, future work will focus on "humanizing" the fungal scaffold to minimize potential immunogenicity and expanding the platform's reach to a broader repertoire of membrane proteins. This unified strategy for protein degradation and drug delivery opens new avenues for treating complex, drug-resistant diseases.

Summary updated

Abstract

<title>Abstract</title> Current lysosome-targeting chimeras (LYTACs) and antibody-drug conjugates (ADCs) face inherent limitations, including reliance on monospecific binders and target-dependent internalization efficiency. Here, we report a versatile therapeutic platform that overcomes these constraints by engineering a novel class of multivalent, multispecific binding proteins, termed <bold>Multibodies</bold> . Using the fungal immunomodulatory protein LZ-8 as a scaffold, we developed a lysosome-targeting chimera-drug conjugates (LYTAC-DCs) system capable of mediating the degradation of multiple membrane proteins while enabling site-specific drug release. While wild-type LZ-8 demonstrated potent lysosomal targeting, it induced significant off-target toxicity and lysosomal dysfunction. Through rational protein engineering, we identified a key residue (Y84) responsible for promiscuous receptor binding and generated an optimized variant, LZ-8-2.3 (Y84A), which eliminated toxicity while preserving efficient lysosomal trafficking. The resulting LYTAC-DC platform mediated high-fidelity degradation of EGFR, PD-L1, and HER2 across diverse cancer models, concurrently delivering cytotoxic (e.g., MMAE) or immunogenic (e.g., doxorubicin) payloads. Efficacy was validated in patient-derived organoids and murine xenografts, including against osimertinib-resistant lung cancer. Furthermore, AI-assisted directed evolution enabled the development of non-chimeric lysosome-targeting drug conjugates (LYTA-DCs), highlighting the modularity and engineerability of the Multibody scaffold. Our work establishes a unified and programmable strategy for targeted protein degradation and drug delivery, significantly expanding the therapeutic landscape beyond conventional LYTAC and ADC technologies.
BibTeX
@inproceedings{wang2026multibody,
  author = {Lei Wang and Luping Chen and Shuai Yao and Xiaoli Tian and li ping and Pan Tan and Qi Sun and Yiyang Gu and Yixuan Wen and Jin Huang and Simin Chen and Dong-Yuan Lv and Wei Wu and Liming Ouyang and Liqiang Fan and Wei Huang and Fujun Wang and Yuzheng Zhao and Jian Zhao and Jingyu Zhang and Hong Liang and Feng Tang},
  title = {{Multibody-Enabled Lysosome-Targeting Drug Conjugates for Target Protein Degradation and Combination Therapy}},
  booktitle = {Research Square},
  year = {2026},
  doi = {10.21203/rs.3.rs-8651044/v1},
}
Figure